Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns
Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.
Crypto Briefing9h
NewsBriefs - Binance addresses sudden drop in ACT token and altcoins, adjusts leverage ratios
Binance issued a statement regarding a significant drop in the Act I: The AI Prophecy (ACT) token and other altcoins on its ...
NEO Battery Materials Collaborates with Elementium Materials Leveraging Advanced Electrolyte Technology
Collaboration Agreement with Elementium Materials, an Advanced Electrolyte Technology CompanyUsing Elementium’s Advanced Electrolytes to Enhance NEO’s Silicon Battery Platform for Specialty Commercial ...
The Punch15h
Dogecoin, Solana & XRP Price Prediction: Trio Set for a Violent Comeback, While Rexas Finance (RXS) Remains Unshaken By Volatility
Rexas Finance (RXS) has emerged as a strong alternative to Cardano (ADA), with predictions indicating a rise to $12 in 2025.